Table 2.
Comparison of the nonrecurrent and recurrent patient groups
| Variable | No recurrence (n = 21) |
Recurrence (n = 6) |
Univariate analysis P-value |
Multivariate analysis OR(95% CI) P-value |
|---|---|---|---|---|
| Sex [male (%)] | 15 (71.4%) | 2 (33.3%) | 0.15 | |
| Age (years) | 76 (63–83) | 79 (66–83) | 0.52 | |
| Length of stay | 15 (10–27) | 14 (9–36) | 0.82 | |
| TG18 grade | ||||
| II | 9 (42.9%) | 3 (50.0%) | 1 | |
| III | 12 (57.1%) | 3 (50.0%) | ||
| aCCI | 4 (3–5) | 5 (4–5) | 0.13 | |
| Preoperative body temperature (℃) | 38.0 (37.2–39.2) | 37.5 (36.6–38.5) | 0.15 | |
| Initial laboratory values | ||||
| Platelets (× 109 L) | 172.0 (114.0–294.0) | 163.50 (101.75–284.25) | 0.77 | |
| White blood cells (× 109 L) | 11.4 (8.6–17.2) | 6.2 (4.2–9.7) | 0.031 | |
| Neutrophil granulocytes (%) | 86.1 (75.5–93.0) | 74.6 (68.0–82.3) | 0.047 | |
| ALT (U/L) | 39.0 (24.5–92.5) | 27.0 (21.7–91.8) | 0.56 | |
| STB (μmol/L) | 20.0 (13.6–33.9) | 17.0 (7.9–23.8) | 0.24 | |
| CB (μmol/L) | 1.4 (0–10.2) | 1.9 (0–5.4) | 0.62 | |
| UCB (μmol/L) | 9.4 (3.7–13.8) | 6.2 (3.5–18.5) | 0.86 | |
| CHD or CHF | 3 (14.3%) | 4 (66.7%) | 0.024 | 26.50 (1.21–582.06) 0.038 |
| Diabetes | 3 (14.3%) | 3 (50.0%) | 0.10 | |
| Cerebrovascular disease | 4 (19.0%) | 3 (50%) | 0.29 | |
| Malignancy | 4 (19.0%) | 2 (33.3%) | 0.59 | |
| Clinical effectiveness | 16 (76.2%) | 5 (83.3%) | 1 |
aCCI age-adjusted Charlson comorbidity index; WBC White blood cells; ALT alanine aminotransferase; STB serum total bilirubin; CB conjugated bilirubin; UCB unconjugated bilirubin; CHD coronary heart disease; CHF congestive heart failure